Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice

Toxicological Sciences

Volumn 139, Issue 2, 2014, Pages 293-300

  Kensler, Kevin H ^a   Slocum, Stephen L ^a   Chartoumpekis, Dionysios V ^b   Dolan, Patrick M ^a   Johnson, Natalie M ^a   Ilic, Zoran ^c   Crawford, Dana R ^d   Sell, Stewart ^c   Groopman, John D ^a   Kensler, Thomas W ^a,b   Egner, Patricia A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WADSWORTH CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Aflatoxin; DNA adducts; Glutathione s transferases; Keap1; Nrf2

Indexed keywords

ACETYLCYSTEINE; AFLATOXIN B1; GLUTATHIONE TRANSFERASE A3; GUANINE DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; CYTOSKELETON PROTEIN; GLUTATHIONE TRANSFERASE; GSTA3 PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; KEAP1 PROTEIN, MOUSE; MUTAGENIC AGENT; NFE2L2 PROTEIN, MOUSE; OLEANOLIC ACID; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; GENE ACTIVATION; GENETIC TRANSCRIPTION; GENOTOXICITY; GENOTYPE; KNOCKOUT MOUSE; LIVER CELL; MALE; MASS SPECTROMETRY; METABOLITE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; URINALYSIS; URINARY EXCRETION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HYPERTENSION; LIVER; METABOLISM; TOXICITY; URINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AFLATOXIN B1; ANIMALS; CYTOSKELETAL PROTEINS; GLUTATHIONE TRANSFERASE; HEPATOCYTES; HYPERTENSION; IMIDAZOLES; LIVER; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTAGENS; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; SIGNAL TRANSDUCTION;

EID: 84899896501     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu056     Document Type: Article

References (49)

1. Bartels, M. J., and Timchalk, C. (1990) 1,2-Dichloropropane: investigation of the mechanism of mercapturic acid formation in the rat. Xenobiotica, 20, 1035-1042.
2. Bartels, M. J., and Miner, V. W. (1989). Synthesis of stable isotopic-labelled analogs of the cysteine and N-acetyl cysteine conjugates of tetrachloroethylene. J. Labelled Compounds Radiopharm. 28, 209-214.
3. Buetler, T. M., Gallagher, E. P., Wang, C.-H.., Stahl, D. L., Hayes, J. D., and Eaton, D. L. (1995). Induction of phase I and phase II drug metabolizing enzyme mRNA, protein and activity by BHA, ethoxyquin and oltipraz. Toxicol. Appl. Pharm., 135, 45-57.
4. Buetler, T. M, Slone, D., and Eaton, D. L. (1992). Comparison of the aflatoxin B1-8,9-epoxide conjugating activities of two bacterially expressed alpha class glutathione S-transferase isozymes from mouse and rat. Biochem. Biophys. Res. Commun. 188, 597-603.
5. Busby, W. F., andWogan, G. N. (1984). Aflatoxins. In: Chemical Carcinogens (C. Searle, Ed.), pp. 945-1136, American Chemical Society, Washington, D.C.
6. Chanas, S. A., Jiang, Q., McMahon, M., McWalter, G. K., McLellan, L. I., Elcombe, C. R., Henderson, C. J., Wolf, C. R., Moffat, G. J., Itoh, K., et al. (2002). Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the GST Gsta1, Gsta2, Gstm1, Gstm3, and Gstm4 genes in the livers of male and female mice. Biochem. J. 365, 405-416.
7. Dinkova-Kostova,A. T., Liby, K. T., Stephenson, K. K., Holtzclaw,W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005). Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. U.S.A. 102, 4584-4589.
8. Eaton, D. L., Bammler, T. K., andKelly, E. J. (2001). Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenisis: Implications for human biotransformation enzyme polymorphisms. Adv. Exp. Med. Biol. 500, 559-576.
9. Eaton, D. L., and Gallagher, E. P. (1994).Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34, 135-172.
10. Egner, P. A., Groopman, J. D., Wang, J. S., Kensler, T. W., and Friesen, M. (2006). Quantification of aflatoxin-B1-N7-Guanine in human urine by highperformance liquid chromatography and isotope dilution tandem mass spectrometry. Chem. Res. Toxicol. 19, 1191-1195.
11. Fields, W. R., Morrow, C. S., Doehmer, J., and Townsend, J. D. (1999). Expression of stably transfected murine glutathione s transferase A3-3 protects against nucleic acid alkylation and cytotoxicity by aflatoxin B1 in hamster V79 cells expressing rat cytochrome P450-2B1. Carcinogenisis 20, 1121-1125.
12. Hayes, J. D., Chanas, S. A., Henderson, C. J., McMahon, M., Sun, C., Moffat, G. J., Wolf, C. R., and Yamamoto, M. (2000). The Nrf2 transcription factor contributes to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans. 28, 33-41.
13. Hayes, J. D., Judah, D. J., McLellan, L. I., and Neal, G. E. (1991). Contribution of the glutathione S-transferase to the mechanisms of resistance to aflatoxin B1. Pharmacol. Ther. 58, 443-472.
14. Henderson, C. J., Smith, A. G., Ure, J., Brown, K., Bacon, E. J., and Wolf, C. R. (1998). Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. U.S.A. 95, 5275-5280.
15. Holmes, D. T., and Buhr, K. A. (2007). Error propagation in calculated ratios. Clin. Biochem. 40, 728-734.
16. Honda, T., Rounds, B. V., Bore, L., Finlay, H. J., Favaloro, F. G., Jr, Suh, N., Wang, Y., Sporn, M. B., and Gribble, G. W. (2000). Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 4233-4246.
17. Iida, K., Itoh, K., Maher, J. M., Kumagai, Y., Oyasu, R., Mori, Y., Shimazui, T., Akaza, H., and Yamamoto, M. (2007). Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis 28, 2398-2403.
18. Ilic, Z., Crawford, D., Vakharia, D., Egner, P. A., and Sell, S. (2010). Glutathione S-transferase A3 knockout mice are sensitive to acute cytotoxic and genotoxic effects of aflatoxin B1. Toxicol. Appl. Pharm. 242, 241-246.
19. Johnson, N. M., Egner, P. A., Baxter, V.K., Sporn, M. B., Wible, R. S., Sutter, T. R., Groopman, J. D., Kensler, T. W., and Roebuck, B. D. Complete protection against aflatoxin B1-induced liver cancer with triterpenoid: DNA adduct dosimetry, molecular signature and genotoxicity threshold. Cancer Prev. Res. doi:10.1158/1940-6207.CAPR-13-0430.
20. Jowsey, I. R., Jiang, Q., Itoh, K., Yamamoto, M., and Hayes, J. D. (2003a). Expression of the aflatoxin B1-8,9-epoxide-metabolizing murine glutathione S-transferase A3 subunit is regulated by the Nrf2 transcription factor through an antioxidant response element. Mol. Pharmacol. 64, 1018-1028.
21. Jowsey, I. R., Smith, S. A., and Hayes, J. D. (2003b). Expression of the murine glutathione S-transferase alpha3 (GSTA3) subunit is markedly induced during adipocyte differentiation: Activation of the GSTA3 gene promoter by the pro-adipogenic eicosanoid 15d-PGJ2. Biochem. Biophys. Res. Commun. 312, 1226-1235.
22. Kensler, T. W., Egner, P. A., Trush, M. A., Bueding, E., and Groopman, J. D. (1985). Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 6, 759-763.
23. Kensler, T. W., Roebuck, B. D., Wogan, G. N., and Groopman, J. D. (2011). Aflatoxin: A 50 year odyssey of mechanistic and translational toxicology. Toxicol. Sci. 120, 28-48.
24. Kitamura, Y., Umemura, T., Kanki, K., Kodama, Y., Kitamoto, S., Saito, K., Itoh, K., Yamamoto,M., Masegi, T., Nishikawa, A., et al. , (2007). Increased susceptibility to hepatocarcinogenicity of Nrf2-deficient mice exposed to 2-amino-3-methylimidizo[4,5]quinoline. Cancer Sci. 98, 19-24.
25. Knight, T. R., Choudhuri, S., and Klaassen, C. D. (2008). Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. Toxicol. Sci. 106, 329-338.
26. Knight, L. P., Primiano, T., Groopman, J. D., Kensler, T. W., and Sutter, T. R. (1999). cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 20, 1215-1223.
27. Liu, J., Wu, K. C., Lu, Y. F., Ekuase, E., and Klaassen, C. D. (2013). Nrf2 protection against liver injury produced by various hepatotoxicants. Oxid. Med. Cell Longev. 2013, 305861.
28. McWalter, G. K., Higgins, L. G., McLellan, L. I., Henderson, C. J., Song, L., Thornalley, P. J., Itoh, K., Yamamoto,M., andHayes, J.D. (2004). Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J. Nutr. 134, 3499S-3506S.
29. Mitchell, A., Morin, D., Lakritz, J., and Jones, A. D. (1997). Quantitative profiling of tissue and gender related expression of GST isoenzymes in the mouse. Biochem. J. 325, 207-216.
30. Nioi, P., McMahon, M., Itoh, K., Yamamoto,M., and Hayes, J. D. (2003). Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone reductase 1 gene: Reassessment of the ARE consensus sequence. Biochem. J. 374, 337-348.
31. Okawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T. W., and Yamamoto, M. (2006). Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 339, 79-88.
32. Okhoshi, A., Suzuki, T., Ono, M., Kobayashi, T., and Yamamoto, M. (2013). Roles of Keap1-Nrf2 system in upper aerodigestive tract carcinogenesis. Cancer Prev. Res. 6, 149-159.
33. Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
34. Prochaska, H. J., and Santamaria, A. B. (1988). Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328-336.
35. Ramos-Gomez, M., Kwak, M. K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., and Kensler, T.W. (2001). Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98, 3410-3415.
36. Ritchie, K. J., Henderson, C. J., Wang, X. J., Vassieva, O., Carrie, D., Farmer, P. B., Gaskell, M., Park, K., and Wolf, C. R. (2007). Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res. 67, 9248-9257.
37. Ritchie, K. J., Walsh, S., Sansom, O. J., Henderson, C. J., and Wolf, C. R. (2009). Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi. Proc. Natl. Acad. Sci. U.S.A. 106, 20859-20864.
38. Roebuck, B. D., Johnson, D. N., Sutter, C. H., Egner, P. A., Scholl, P. F., Friesen, M. D., Baumgartner, K. J., Ware, N. M., Bodreddigari, S. B., Groopman, J. D., et al. (2009). Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat. Toxicol. Sci. 109, 41-49.
39. Scholl, P. F., Musser, S. M., and Groopman, J. D. (1997). Synthesis and characterization of aflatoxin B1 mercapturic acids and their identification in rat urine. Chem. Res. Toxicol. 10, 1144-1151.
40. Shupe, T., and Sell, S. (2004). Low hepatic S-transferase and increased hepatic DNA adduction contribute to increased tumorigenicity of aflatoxin B1 in newborn and partially hepatectomized mice. Toxicol. Lett. 148, 1-9.
41. Slocum, S. L., and Kensler, T. W. (2011). Nrf2: Control of sensitivity to carcinogens. Arch. Toxicol. 85, 273-284.
42. Vesselinovitch, S. D., Mihailovich, N., Wogan, G. N., Lombard, L. S., and Rao, K. V.N. (1972).Aflatoxin B1, a hepatocarcinogen in the infant mouse. Cancer Res. 32, 2289-2291.
43. Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003). Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238-245.
44. Wang, J. S., Shen, X., He, X., Zhu, Y. R., Zhang, B. C.,Wang, J. B., Qian, G. S., Kuang, S. Y., Zarba, A., Egner, P. A., et al. (1999). Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl. Cancer Inst. 91, 347-354.
45. Wang, X., Spandidos, A., Wang, H., and Seed, B. (2012). PrimerBank: A PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40, D1144-D1149.
46. Xu, C., Huang, M. T., Shen, G., Yuan, X., Lin, W., Khor, T. O., Conney, A. H., and Kong, A. N. (2006). Inhibition of 7,12-dimethylbenza[a]anthraceneinduced skin tumorigenesis in C57BL6/J mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res. 66, 8293-8296.
47. Yates,M. S., and Kensler, T.W. (2007) Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol. Sin., 28, 1331-1342.
48. Yates,M. S., Kwak, M., Egner, P. A., Groopman, J. D., Bodreddigari, S., Sutter, T. R., Baumgartner, K. J., Roebuck, B. D., Liby, K. T., Yore, M. M., et al. (2006). Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-12-dioxooleana-1,9(11)-dien-28-ol = yl]imidazole. Cancer Res.66, 2488-2494.
49. Yates, M. S., Tauchi, M., Katsuoka, F., Flanders, K. C., Liby, K. L., Honda, T., Gribble,, Johnson, D. A., Johnson, J. A., Burton, N. C., et al. (2007). Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 6, 154-162.